2012
DOI: 10.1038/leu.2012.202
|View full text |Cite
|
Sign up to set email alerts
|

Encapsulated mesenchymal stem cells for in vivo immunomodulation

Abstract: Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
54
1

Year Published

2015
2015
2022
2022

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 70 publications
(58 citation statements)
references
References 18 publications
1
54
1
Order By: Relevance
“…Alginate has been used before to protect cells against the host immune system (Herrero et al, 2007;Kang et al, 2014;Zanotti et al, 2013). Although in our in vitro assay, alginate appeared to stimulate the proliferation of stimulated T cells, when MSCs were encapsulated, the alginate constructs inhibited T cell proliferation.…”
Section: Mjc Leijs Et Al Encapsulation Of Mscs In Alginatementioning
confidence: 52%
See 1 more Smart Citation
“…Alginate has been used before to protect cells against the host immune system (Herrero et al, 2007;Kang et al, 2014;Zanotti et al, 2013). Although in our in vitro assay, alginate appeared to stimulate the proliferation of stimulated T cells, when MSCs were encapsulated, the alginate constructs inhibited T cell proliferation.…”
Section: Mjc Leijs Et Al Encapsulation Of Mscs In Alginatementioning
confidence: 52%
“…Alginate, a natural polysaccharide isolated from brown seaweed, is the most common used gel for cell encapsulation due to its biocompatibility and stability in vivo (de Vos et al, 2002;Shoichet and Rein, 1996;Wu et al, 2007;Murua et al, 2008). Moreover, alginate has the capacity to protect encapsulated cells against recognition by the immune system (Barminko et al, 2011;Herrero et al, 2007;Kang et al, 2014;Trouche et al, 2010;Zanotti et al, 2013), which will enable the use of allogeneic cells. This would greatly enhance the clinical translatability of MSCs-based therapies.…”
Section: Introductionmentioning
confidence: 99%
“…In animals that received alginate-encapsulated MSCs, a trend of decrease of the cumulative histologic score, inflammatory cell infiltration and tissue damage was revealed in the liver. The numerous foci of lymphoid cells infiltrating hepatic lobules characteristic of GVHD livers, were also reduced following treatment with encapsulated-MSCs [56]. Strikingly, GVHD mice that did not receive MSCs or received iv MSC injection died between day 6 and 13 after transplantation, while the treatment with subcutaneously-injected alginate-encapsulated MSCs significantly increased survival rate and clinical score of GVHD mice on day 8 [56].…”
Section: Immunomodulationmentioning
confidence: 82%
“…1), and successfully differentiated as directed (6). Alginate also exhibits excellent in vivo stability (29). However, multiple factors can influence alginate-based capsule stability after transplantation, such as the implantation site and capsule composition (30).…”
Section: Bioencapsulation Materials and Methodsmentioning
confidence: 99%